nach oben

Erschienen in:

01.01.2013 | Original Article

BMD improvements after operation for primary hyperparathyroidism

verfasst von: Lars Rolighed, Peter Vestergaard, Lene Heickendorff, Tanja Sikjaer, Lars Rejnmark, Leif Mosekilde, Peer Christiansen

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to quantify bone mineral density (BMD) changes following surgery in patients with primary hyperparathyroidism (PHPT) and to assess their relationship with clinical and biochemical variables.

Methods

A historic cohort of 236 PHPT patients with DXA scans pre- and 1-year postoperatively, clinical data, and biochemical data was analyzed.

Results

The mean age was 60 years (range 19–86) and 81 % of the patients were women. A significant postoperative 2.6 % (95 % CI, 2.1; 3.1) increase in lumbar spine BMD was seen. The increase in BMD was positively associated with preoperative plasma PTH (p = 0.002), Ca²⁺ (p < 0.001), and alkaline phosphatase (p = 0.014). Hip BMD increased 1.5 % (1.1; 1.9). The increase in BMD was positively associated with preoperative plasma PTH (p = 0.005) and Ca²⁺ (p < 0.001) and inversely associated with plasma creatinine (p = 0.004) and age (p = 0.018). Total forearm BMD did not change significantly (−0.2 % (−0.5; 0.1)). An increase in forearm BMD was seen in 38 % of all patients, and the changes were positively associated with plasma PTH (p < 0.001) and Ca²⁺ (p = 0.009). In all 91 patients with mild PHPT (plasma Ca²⁺ < 1.45 mmol/l), there was a significant postoperative increase in spine BMD (1.9 % (1.2; 2.7)) and in hip BMD (1.0 % (0.4; 1.6)), but not in the forearm BMD (−0.3 % (−0.7; 0.2)). The postoperative BMD gain was higher in the hip and forearm in patients operated for adenomas compared with patients treated for hyperplasia.

Conclusions

We found significant postoperative BMD improvements both at the hip and the spine. BMD improvements were also significant in mild cases. At all scan sites, there were positive associations between preoperative plasma PTH levels and postoperative BMD increases. The measured BMD changes may mainly be due to a decrease in PTH-induced bone turnover with refilling of the remodeling space.

Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94(2):335–339PubMedCrossRef

Bollerslev J, Marcocci C, Sosa M, Nordenstrom J, Bouillon R, Mosekilde L (2011) Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol 165(6):851–864PubMedCrossRef

Parfitt AM, Rao DS, Kleerekoper M (1991) Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 6(Suppl 2):S97–S101, discussion S121-S124PubMed

NIH (1991) NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 114(7):593–597

Bilezikian JP, Potts JT Jr, Fuleihan G, Kleerekoper M, Neer R, Peacock M et al (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87(12):5353–5361PubMedCrossRef

Bergenfelz AO, Hellman P, Harrison B, Sitges-Serra A, Dralle H, European Society of Endocrine Surgeons (2009) Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbecks Arch Surg 394(5):761–764CrossRef

Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E et al (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93(9):3462–3470PubMedCrossRef

Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341(17):1249–1255PubMedCrossRef

Rubin MR, Lee KH, McMahon DJ, Silverberg SJ (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88(3):1174–1178PubMedCrossRef

10.

Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ (2005) Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 90(6):3326–3330PubMedCrossRef

11.

Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O et al (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92(5):1687–1692PubMedCrossRef

12.

Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92(8):3114–3121PubMedCrossRef

13.

Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89(11):5415–5422PubMedCrossRef

14.

Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):340–350PubMedCrossRef

15.

Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365PubMedCrossRef

16.

Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69(1):1–19CrossRef

17.

Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P et al (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21(1):93–99PubMedCrossRef

18.

Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L et al (1999) Primary hyperparathyroidism: whole-body bone mineral density in surgically treated Danish patients: a three-year follow-up study. Bone 25(5):597–602PubMedCrossRef

19.

Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L et al (1999) Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone 25(5):589–595PubMedCrossRef

20.

Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L (2008) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68(5):707–715CrossRef

21.

Hojskov CS, Heickendorff L, Moller HJ (2010) High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clin Chim Acta 411(1–2):114–116PubMedCrossRef

22.

Abrahamsen B, Gram J, Hansen TB, Beck-Nielsen H (1995) Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone 16(3):385–390PubMedCrossRef

23.

Lafferty FW (1981) Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med 141(13):1761–1766PubMedCrossRef

24.

Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005PubMedCrossRef

25.

Lafferty FW (1991) Differential diagnosis of hypercalcemia. J Bone Miner Res 6(Suppl 2):S51–S59, discussion S61PubMed

26.

Sankaran S, Gamble G, Bolland M, Reid IR, Grey A (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 95(4):1653–1662PubMedCrossRef

27.

Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90(1):135–141PubMedCrossRef

28.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY et al (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(7):3319–3325PubMedCrossRef

29.

Vestergaard P (2006) Current pharmacological options for the management of primary hyperparathyroidism. Drugs 66(17):2189–2211PubMedCrossRef

30.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348(9041):1535–1541PubMedCrossRef

31.

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):540–551PubMedCrossRef

32.

VanderWalde LH, Liu IL, O’Connell TX, Haigh PI (2006) The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism. Arch Surg 141(9):885–889, discussion 889–891PubMedCrossRef

33.

Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90(4):2122–2126PubMedCrossRef

34.

Kantorovich V, Gacad MA, Seeger LL, Adams JS (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85(10):3541–3543PubMedCrossRef

35.

Isidro ML, Ruano B (2009) Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36(2):305–310PubMedCrossRef

36.

Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB et al (2008) Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 144(6):852–858, discussion 858–859PubMedCrossRef

37.

Rolighed L, Bollerslev J, Mosekilde L (2011) Vitamin D treatment in primary hyperparathyroidism. Curr Drug Saf 6(2):100–107PubMedCrossRef

38.

Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107(6):561–567PubMedCrossRef

39.

Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC (2006) A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29(6):511–515PubMed

40.

Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L (2005) Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63(5):506–513CrossRef

41.

Amstrup AK, Rejnmark L, Vestergaard P, Sikjaer T, Rolighed L, Heickendorff L et al (2011) Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls—a cross-sectional study. Clin Endocrinol (Oxf) 74(1):130–136CrossRef

42.

Lind L, Wengle B, Wide L, Sorensen OH, Ljunghall S (1988) Hypertension in primary hyperparathyroidism—reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study. Am J Hypertens 1(4 Pt 1):397–402PubMed

43.

Vestergaard P, Thomsen SS (2011) Medical treatment of primary, secondary, and tertiary hyperparathyroidism. Curr Drug Saf 6(2):108–113PubMed

44.

Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J (2004) Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery 136(6):1281–1288PubMedCrossRef

45.

Steiniche T, Christiansen P, Vesterby A, Ullerup R, Hessov I, Mosekilde LE et al (2000) Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 26(5):535–543PubMedCrossRef

46.

Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K (2012) Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism. A 1-year prospective controlled study using high resolution peripheral quantitative computed tomography. J Bone Miner Res 27(5):1150–1158PubMedCrossRef

47.

Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321(7261):598–602PubMedCrossRef

48.

Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14(10):1700–1707PubMedCrossRef

49.

Sitges-Serra A, Garcia L, Prieto R, Pena MJ, Nogues X, Sancho JJ (2010) Effect of parathyroidectomy for primary hyperparathyroidism on bone mineral density in postmenopausal women. Br J Surg 97(7):1013–1019PubMedCrossRef

50.

Walker MD, Dempster DW, McMahon DJ, Udesky J, Shane E, Bilezikian JP et al (2012) Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab 97(5):1501–1507PubMedCrossRef

51.

Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR (1998) Hormonal predictors of bone loss in elderly women: a prospective study. The study of osteoporotic fractures research group. J Bone Miner Res 13(7):1167–1174PubMedCrossRef

52.

Christiansen P (2001) The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture. APMIS 109(Suppl 102):1–52

53.

Amstrup AK, Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2010) Effects of smoking on severity of disease in primary hyperparathyroidism. Calcif Tissue Int 87(5):406–413PubMedCrossRef

54.

Yeh MW, Wiseman JE, Ituarte PH, Pasternak JD, Hwang RS, Wu B et al (2012) Surgery for primary hyperparathyroidism: are the consensus guidelines being followed? Ann Surg 255(6):1179–1183PubMedCrossRef

55.

Langdahl BL, Ralston SH (2012) Diagnosis and management of primary hyperparathyroidism in Europe. QJM 105(6):519–525PubMedCrossRef

Titel: BMD improvements after operation for primary hyperparathyroidism
verfasst von: Lars Rolighed
Peter Vestergaard
Lene Heickendorff
Tanja Sikjaer
Lars Rejnmark
Leif Mosekilde
Peer Christiansen
Publikationsdatum: 01.01.2013
Verlag: Springer-Verlag
Erschienen in: Langenbeck's Archives of Surgery / Ausgabe 1/2013
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-012-1026-5

Neu im Fachgebiet Chirurgie

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

BMD improvements after operation for primary hyperparathyroidism